Alpha Tau Q1 2026 Results: Positive Glioblastoma Data and Completion of ReSTART Trial Enrollment

Alpha Tau Medical Ltd. reported first quarter 2026 financial results and provided a significant corporate update. The company reported a net loss of $22.9 million for Q1 2026, compared to $8.7 million in the prior year, with $80.2 million in cash and deposits providing a runway for continued operations. Key clinical highlights include groundbreaking interim results from the U.S. REGAIN trial in recurrent glioblastoma, showing 100% local disease control and a 67% complete response rate in the first three patients. The company also announced the completion of patient enrollment (88 patients) in its U.S. pivotal ReSTART trial for recurrent cutaneous squamous cell carcinoma, a major milestone toward potential FDA pre-market approval. Additionally, Alpha Tau received FDA approval for an IDE supplement to expand its IMPACT pancreatic cancer trial. The company expects top-line data from the ReSTART trial and additional REGAIN data by the end of 2026, with initial IMPACT pancreatic data targeted for late 2026 or early 2027.